Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData, Phase II drugs for Natural Killer Cell Lymphomas have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Linperlisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Linperlisib overview

Linperlisib (Intarel) is an antineoplastic agent. It is formulated as a tablet for the oral route of administration. Intarel is indicated for the treatment of adult patients with relapsed and refractory follicular lymphoma who have received at least two systemic treatments in the past.

YY-20394 is under development for the treatment of recurrent or refractory peripheral t-cell lymphoma, relapsed and refractory diffuse large B-cell lymphoma, relapsed/refractory thymic cancer, unspecified T-cell lymphomas, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, ALK-positive and negative resistance large cell lymphoma, mantle cell lymphoma, B-cell non-Hodgkin lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and other PTCL subtypes, follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, solid tumors and B-cell hematological malignancies, nasopharyngeal Cancer, head and neck cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, gallbladder cancer, cholangiocarcinoma, pancreatic cancer, urothelial carcinoma, renal cell carcinoma cancer, ovarian cancer, endometrial cancer, relapsed / refractory autoimmune hemolytic anemia and relapsed/refractory large granular t lymphocytic leukemia. The drug candidate is administered orally. It acts by targeting PI3 kinase delta.

Shanghai Yingli Pharmaceutical overview

Shanghai Yingli Pharmaceutical (Yingli) is a pharmaceutical company focused on discovery and development of innovative small molecule drugs for the treatment of cancer, autoimmune diseases, and metabolic disorders. Yingli is headquartered in Shanghai, China.

For a complete picture of Linperlisib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.